SWS Academic Research eLibraryEarth & Planetary Sciences

Scholarly record

DEVELOPMENT OF LIPOSOMAL VESICLES WITH BRIMONIDINE TARTRATE AS DERMAL DRUG DELIVERY SYSTEMS

Student Pharm. Manuela Hortolomei

First published: 2015-06-20https://doi.org/10.5593/sgem2015/b61/s24.007View metrics

Publication Impact Profile

PlumX
  • Captures
  • Mendeley - Readers: 5
PLUMX see details

Publication details

Title
DEVELOPMENT OF LIPOSOMAL VESICLES WITH BRIMONIDINE TARTRATE AS DERMAL DRUG DELIVERY SYSTEMS
Authors
Student Pharm. Manuela Hortolomei
Proceedings
SGEM International Multidisciplinary Scientific GeoConference EXPO Proceedings; 15th International Multidisciplinary Scientific GeoConference SGEM2015, NANO, BIO AND GREEN TECHNOLOGIES FOR A SUSTAINABLE FUTURE
Publisher
Stef92 Technology
Year
2015
Pages
45-52
ISSN
1314-2704
ISBN
978-619-7105-42-1
Language
en
Publication type
Conference Paper
Keywords
Environmental LegislationMultilateral Relations and Funding Opportunities
References30

  1. Ki m J.H., Oh Y.S., Ji J.H., Bak H., Ahn S.K. Rosacea (erythematotelangiectatic type) effectively improved by topical xylometazoline. J Dermatol, 38: 510-513, 2011.

  2. Fleischer AB. Inflammation in rosacea and acne: implications for patient care. J Drugs Dermatol, 10: 614-620, 2011.

  3. Maier LE. Rosacea: advances in understanding pathogenesis and treatment. Clin Invest 1: 739-755, 2011.

  4. Yamasaki K., Gallo R.L. The molecular pathology of rosacea. J Dermatol Sci, 55: 77-81, 2009 .

  5. Goldgar C, Keahey DJ, Houchins J. Treatment o ptions for acne rosacea. Am Fam Physician 80: 461-468, 2009.

  6. Bladwin H. Oral therapy for rosacea. J Drugs Dermatol. 5: 16-21, 2006.

  7. Nally J, Berson D. Topical therapies for rosacea. J Drugs Dermatol . 5: 23-27, 2006.

  8. Piwnica D. Rosignoli C., Thibaut S. et a l. Vasoconstriction and anti-inflammatory properties of the selective α-adrenergic receptor agonist brimonidine. J Dermatol Sci, 75: 49 – 54, 2014.

  9. Hieble J.P. Subclassification and nomenclature of alpha and beta-adrenoreceptors. Curr Top Med Chem, 7: 129-134, 2007.

  10. Piascik M.T., Perez D.M. Alpha1-adrenergic receptors: new insights and directions. J Pharmacol Exp Ther, 298: 403-410, 2001.

  11. Moore A, Kemper S, Murakawa G et al. Long-term safety and efficacy of once - daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of a 1-year open-label study. J Drugs Dermatol 13 (1): 56-61, 2014.

  12. *** Case letter J Am Acad Dermatol, February 2014 e37.

  13. Ochiuz L. , Hortolomei M., Popovici I., Popa M, Peptu A.C., Cadinoiu A.N. Preparation and characterization of large multilamel lar vesicles loaded with brimonidine tartrate. Practica Farmaceutica, 7(3): 144-148, 2014.

  14. Liu H, Tang R, He XX, Zhang Y, Effects of liposomes formulation and preparation method on the stability of acyclovir palmitate liposomes, Acta Pharmaceutica Sinica, 37(7):563-6, 2002

  15. M. M. Nounou et al. In vitro release of hydrophilic and hydrophobic drugs from liposomal dispersions and gels. Acta Pharm 56: 311–324, 2006. International Multidisciplinary Scientific GeoConfenferences SGEM 2015 www.sgem.org

  16. Ki m J.H., Oh Y.S., Ji J.H., Bak H., Ahn S.K. Rosacea (erythematotelangiectatic type) effectively improved by topical xylometazoline. J Dermatol, 38: 510-513, 2011.

  17. Fleischer AB. Inflammation in rosacea and acne: implications for patient care. J Drugs Dermatol, 10: 614-620, 2011.

  18. Maier LE. Rosacea: advances in understanding pathogenesis and treatment. Clin Invest 1: 739-755, 2011.

  19. Yamasaki K., Gallo R.L. The molecular pathology of rosacea. J Dermatol Sci, 55: 77-81, 2009 .

  20. Goldgar C, Keahey DJ, Houchins J. Treatment o ptions for acne rosacea. Am Fam Physician 80: 461-468, 2009.

  21. Bladwin H. Oral therapy for rosacea. J Drugs Dermatol. 5: 16-21, 2006.

  22. Nally J, Berson D. Topical therapies for rosacea. J Drugs Dermatol . 5: 23-27, 2006.

  23. Piwnica D. Rosignoli C., Thibaut S. et a l. Vasoconstriction and anti-inflammatory properties of the selective α-adrenergic receptor agonist brimonidine. J Dermatol Sci, 75: 49 – 54, 2014.

  24. Hieble J.P. Subclassification and nomenclature of alpha and beta-adrenoreceptors. Curr Top Med Chem, 7: 129-134, 2007.

  25. Piascik M.T., Perez D.M. Alpha1-adrenergic receptors: new insights and directions. J Pharmacol Exp Ther, 298: 403-410, 2001.

  26. Moore A, Kemper S, Murakawa G et al. Long-term safety and efficacy of once - daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of a 1-year open-label study. J Drugs Dermatol 13 (1): 56-61, 2014.

  27. *** Case letter J Am Acad Dermatol, February 2014 e37.

  28. Ochiuz L. , Hortolomei M., Popovici I., Popa M, Peptu A.C., Cadinoiu A.N. Preparation and characterization of large multilamel lar vesicles loaded with brimonidine tartrate. Practica Farmaceutica, 7(3): 144-148, 2014.

  29. Liu H, Tang R, He XX, Zhang Y, Effects of liposomes formulation and preparation method on the stability of acyclovir palmitate liposomes, Acta Pharmaceutica Sinica, 37(7):563-6, 2002

  30. M. M. Nounou et al. In vitro release of hydrophilic and hydrophobic drugs from liposomal dispersions and gels. Acta Pharm 56: 311–324, 2006. International Multidisciplinary Scientific GeoConfenferences SGEM 2015 www.sgem.org

View or Download full articleAccess options
Full paper accessChoose SWS login, librarian support, or instant article download.

SWS access login

Login as SWS Scientific Committee

Authors and approved SWS contributors will read and export their own linked papers after identity matching by SWS profile, email and SGEM GlobalID.

For librarian assistance: [email protected]

Purchase Instant Access

48-hour online accessComing soon
Online-only accessComing soon
Download the full article in PDF formatEUR 35
  • Article can be downloaded after successful payment.
  • Article may be used according to SWS library access terms.
  • Article cannot be redistributed.
Get full paper

Back to publication list